An article in the March 10, 2017, issue of The ASCO Post reported on a presentation from the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, noting that the investigational drug pacritinib has been shown to reduce spleen volume in myelofibrosis. The article erroneously stated that the drug remained on U.S. Food and Drug Administration (FDA)-imposed clinical hold after concerns about toxicity.
In fact, although at the time of the ASH presentation, pacritinib had been on hold since February 2016, the FDA lifted that hold in January 2017.
A corrected version of the article is available online at http://bit.ly/2mJsmj2. ■
